Furthermore, atezolizumab was approved in combination with paclitaxel and carboplatin to treat metastatic non-squamous NSCLC without EGFR or ALK genomic aberrations based on the IMpower-130, which was a multicenter, randomized, open-label, phase III trial and aimed to assess the clinical efficacy and safety of atezolizumab in combination with chemotherapy versus chemotherapy alone to treat non-squamous NSCLC (69). Here, EGFR is linked to non-small cell lung carcinoma.